Results 131 to 140 of about 458,085 (304)

Adenosine A3 receptor antagonists as anti‐tumor treatment in human prostate cancer: an in vitro study

open access: yesFEBS Open Bio, EarlyView.
The A3 adenosine receptors (A3ARs) are overexpressed in prostate cancer. AR 292 and AR 357, as A3AR antagonists, are capable of blocking proliferation, modulating the expression of drug transporter genes involved in chemoresistance, ferroptosis, and the hypoxia response, and inducing cell death.
Maria Beatrice Morelli   +15 more
wiley   +1 more source

Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab

open access: yesJournal for ImmunoTherapy of Cancer, 2018
Background Previous studies have suggested that elevated neutrophil-to-lymphocyte ratio (NLR) is prognostic for worse outcomes in patients with a variety of solid cancers, including those treated with immune checkpoint inhibitors.
Mariaelena Capone   +12 more
doaj   +1 more source

Possible role of human ribonuclease dicer in the regulation of R loops

open access: yesFEBS Open Bio, EarlyView.
R loops play an important role in regulating key cellular processes such as replication, transcription, centromere stabilization, or control of telomere length. However, the unscheduled accumulation of R loops can cause many diseases, including cancer, and neurodegenerative or inflammatory disorders. Interestingly, accumulating data indicate a possible
Klaudia Wojcik   +2 more
wiley   +1 more source

Spontaneous regression of melanoma. Report of a case [PDF]

open access: bronze, 1953
Wilbur C. Sumner
openalex   +1 more source

Understanding and Overcoming Immunotherapy Resistance in Skin Cancer: Mechanisms and Strategies

open access: yesAging and Cancer, EarlyView.
This narrative review explores the mechanisms driving immunotherapy resistance in skin cancer, including tumor microenvironment factors, genetic mutations, and immune evasion strategies. It highlights potential strategies to overcome resistance, offering insights for improving therapeutic outcomes and guiding future research in personalized ...
Shreya Singh Beniwal   +8 more
wiley   +1 more source

Comparison of seventh and eighth edition of AJCC staging system in melanomas at locoregional stage

open access: yesWorld Journal of Surgical Oncology, 2019
Background The eighth edition of the American Joint Committee on Cancer (AJCC) staging system has been effective since January 2018. It has introduced some major changes in the localized/locoregional melanoma classification.
Pawel Teterycz   +3 more
doaj   +1 more source

Perspective: Melanoma diagnosis and monitoring: Sunrise for melanoma therapy but early detection remains in the shade [PDF]

open access: yesarXiv, 2015
Melanoma is one of the most dangerous forms of cancer. The five-year survival rate is 98% if it is detected early. However, this rate plummets to 63% for regional disease and 17% when tumors have metastasized, that is, spread to distant sites. Furthermore, the incidence of melanoma has been rising by about 3% per year, whereas the incidence of cancers ...
arxiv  

T2‐weighted imaging of rectal cancer using a 3D fast spin echo sequence with and without deep learning reconstruction: A reader study

open access: yesJournal of Applied Clinical Medical Physics, EarlyView.
Abstract Purpose To compare image quality and clinical utility of a T2‐weighted (T2W) 3‐dimensional (3D) fast spin echo (FSE) sequence using deep learning reconstruction (DLR) versus conventional reconstruction for rectal magnetic resonance imaging (MRI).
Dan Nguyen   +11 more
wiley   +1 more source

Multidisciplinary Management of Palpebral Melanoma

open access: yesPlastic and Reconstructive Surgery, Global Open
Summary:. Ocular melanoma encompasses the uveal tract, conjunctiva, eyelid, and orbit. Palpebral localization is extremely infrequent, constituting less than 1% of skin melanomas, the main treatment of which is surgical.
Marcelo Chávez Díaz, MD   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy